November 9, 2019 at 4:21 am

Fresenius SE & Co KGaA (FRA:FRE) Given a €53.00 Price Target at Goldman Sachs Group

by

Goldman Sachs Group set a €53.00 ($61.63) price target on Fresenius SE & Co KGaA (FRA:FRE) in a report published on Tuesday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

FRE has been the topic of several other research reports. Morgan Stanley set a €50.00 ($58.14) price target on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research note on Monday, September 30th. Berenberg Bank set a €74.80 ($86.98) price target on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research note on Tuesday, October 29th. Jefferies Financial Group set a €43.00 ($50.00) price target on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research note on Tuesday, October 29th. HSBC set a €52.00 ($60.47) price target on shares of Fresenius SE & Co KGaA and gave the company a neutral rating in a research note on Thursday, October 17th. Finally, DZ Bank restated a buy rating on shares of Fresenius SE & Co KGaA in a research note on Monday, November 4th. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of €57.98 ($67.42).

Shares of FRA:FRE opened at €48.40 ($56.28) on Tuesday. The firm’s 50 day moving average is €44.04 and its two-hundred day moving average is €45.93. Fresenius SE & Co KGaA has a 52 week low of €60.16 ($69.95) and a 52 week high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: Treasury Bonds

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Leave a Comment

Your email address will not be published. Required fields are marked *